3.75

5.54% -0.22

Xeris Biopharma Holdings Inc (XERS)

Overview News Price History Option Chain Financials Discussions Forecast

Xeris Biopharma Holdings Inc stock is traded at $3.75, with a volume of 2.29M. It is down -5.54% in the last 24 hours and up +12.28% over the past month. Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Previous Close:

$3.97

Open:

$4.01

24h Volume:

2.29M

Relative Volume:

1.48

Market Cap:

$559.06M

Revenue:

$181.41M

Net Income/Loss:

$-59.56M

P/E Ratio:

-8.9286

EPS:

-0.42

Net Cash Flow:

$-38.83M

1W Performance:

+4.46%

1M Performance:

+12.28%

6M Performance:

+32.04%

1Y Performance:

+25.00%

1-Day Range:

$3.69

$4.0103

1-Week Range:

$3.5599

$4.10

52-Week Range:

$1.69

$4.10

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Name

Xeris Biopharma Holdings Inc

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

844-445-5704

Address

1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL

Employee

377

Twitter

@XerisPharma

Next Earnings Date

2024-12-08

Latest SEC Filings

XERS's Discussions on Twitter

Compare XERS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XERS Xeris Biopharma Holdings Inc	3.75	559.06M	181.41M	-59.56M	-38.83M	-0.42
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Mar-28-24	Initiated	Oppenheimer	Outperform
Aug-28-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Craig Hallum	Buy
Nov-17-21	Initiated	SVB Leerink	Outperform
Oct-29-21	Initiated	H.C. Wainwright	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-18-20	Initiated	Piper Sandler	Overweight
Jul-16-18	Initiated	Jefferies	Buy
Jul-16-18	Initiated	Leerink Partners	Outperform
Jul-16-18	Initiated	RBC Capital Mkts	Outperform

View All

Xeris Biopharma Holdings Inc Stock (XERS) Latest News

Feb 19, 2025

Who Really Controls Xeris Biopharma? The Retail Investors’ Unseen Power - DSA

Feb 19, 2025

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 50% stake, while 45% is held by institutions - Yahoo Finance

Feb 19, 2025

Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High – Still a Buy? - Defense World

Feb 19, 2025

Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month HighStill a Buy? - MarketBeat

Feb 19, 2025

Feb 18, 2025

Xeris Pharmaceuticals stock hits 52-week high of $3.87 - Investing.com India

Feb 18, 2025

Xeris Pharmaceuticals stock hits 52-week high of $3.87 By Investing.com - Investing.com South Africa

Feb 18, 2025

Legato Capital Management LLC Purchases Shares of 142,164 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat

Feb 18, 2025

Feb 14, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stake Raised by Janney Montgomery Scott LLC - Defense World

Feb 14, 2025

Feb 10, 2025

Take off with Xeris Biopharma Holdings Inc (XERS): Get ready for trading - SETE News

Feb 10, 2025

Feb 07, 2025